These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9835506)

  • 1. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.
    Wasan KM; Kennedy AL; Cassidy SM; Ramaswamy M; Holtorf L; Chou JW; Pritchard PH
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3146-52. PubMed ID: 9835506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
    Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content.
    Kennedy AL; Wasan KM
    J Pharm Sci; 1999 Nov; 88(11):1149-55. PubMed ID: 10564063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits.
    Kwong EH; Ramaswamy M; Bauer EA; Hartsel SC; Wasan KM
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2060-3. PubMed ID: 11408223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
    Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
    J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats.
    Bhamra R; Sa'ad A; Bolcsak LE; Janoff AS; Swenson CE
    Antimicrob Agents Chemother; 1997 May; 41(5):886-92. PubMed ID: 9145839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
    Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
    J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
    Walsh TJ; Whitcomb P; Piscitelli S; Figg WD; Hill S; Chanock SJ; Jarosinski P; Gupta R; Pizzo PA
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1944-8. PubMed ID: 9303390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B lipid complex.
    Rapp RP; Gubbins PO; Evans ME
    Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM; Lumbreras C; González-Vidal D;
    Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.
    Groll AH; Lyman CA; Petraitis V; Petraitiene R; Armstrong D; Mickiene D; Alfaro RM; Schaufele RL; Sein T; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3418-23. PubMed ID: 17005824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
    Cannon JP; Fiscella R; Pattharachayakul S; Garey KW; De Alba F; Piscitelli S; Edward DP; Danziger LH
    Invest Ophthalmol Vis Sci; 2003 May; 44(5):2112-7. PubMed ID: 12714650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study.
    Slain D; Miller K; Khakoo R; Fisher M; Wierman T; Jozefczyk K
    Clin Ther; 2002 Oct; 24(10):1636-42. PubMed ID: 12462292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model.
    Vadiei K; Lopez-Berestein G; Luke DR
    Int J Obes; 1990 Jun; 14(6):465-72. PubMed ID: 2401582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model.
    Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
    Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.
    Adedoyin A; Swenson CE; Bolcsak LE; Hellmann A; Radowska D; Horwith G; Janoff AS; Branch RA
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2900-2. PubMed ID: 10991885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the method by which plasma is separated from whole blood influences amphotericin B plasma recovery and distribution following amphotericin B lipid complex incubation within whole blood.
    Ramaswamy M; Wasan KM
    Drug Dev Ind Pharm; 2001 Sep; 27(8):871-5. PubMed ID: 11699840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
    Sharkey PK; Graybill JR; Johnson ES; Hausrath SG; Pollard RB; Kolokathis A; Mildvan D; Fan-Havard P; Eng RH; Patterson TF; Pottage JC; Simberkoff MS; Wolf J; Meyer RD; Gupta R; Lee LW; Gordon DS
    Clin Infect Dis; 1996 Feb; 22(2):315-21. PubMed ID: 8838189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.